艾德生物(300685) - 2024 Q1 - 季度财报

Financial Performance - Revenue for the first quarter of 2024 was RMB 233.29 million, a 19.53% increase compared to the same period last year[5] - Net profit attributable to shareholders of the listed company was RMB 64.20 million, up 12.01% year-on-year[5] - Total revenue for the first quarter of 2024 reached 233.29 million yuan, a 19.5% increase compared to 195.16 million yuan in the same period last year[20] - Net profit for the first quarter of 2024 was 64.20 million yuan, up 12.0% from 57.32 million yuan in the previous year[20] - Operating profit for the first quarter of 2024 stood at 74.95 million yuan, a 14.4% increase from 65.49 million yuan in the same period last year[21] - Basic earnings per share for the first quarter of 2024 were 0.16 yuan, up from 0.14 yuan in the same period last year[22] - Basic earnings per share increased by 14.29% to RMB 0.16[5] Cash Flow - Net cash flow from operating activities increased by 19.27% to RMB 80.58 million[5] - Net cash flow from investment activities was RMB 50.99 million, a significant improvement from a net outflow of RMB 88.18 million in the same period last year[10] - Cash flow from operating activities for the first quarter of 2024 was 256.34 million yuan, a 19.2% increase compared to 215.06 million yuan in the previous year[24] - Operating cash inflow totaled 273.69 million yuan, an increase from 231.65 million yuan in the previous period[25] - Operating cash outflow was 193.11 million yuan, up from 164.10 million yuan[25] - Net cash flow from operating activities reached 80.58 million yuan, compared to 67.56 million yuan[25] - Investment cash inflow was 200.32 million yuan, significantly higher than 106.43 million yuan[25] - Net cash flow from investment activities was 50.99 million yuan, a turnaround from -88.18 million yuan[25] - Net cash flow from financing activities was -6.26 million yuan, an improvement from -13.39 million yuan[26] - The net increase in cash and cash equivalents was 122.67 million yuan, compared to a decrease of 37.80 million yuan[26] - Ending cash and cash equivalents balance stood at 323.75 million yuan, up from 205.80 million yuan[26] - Cash paid for employee compensation and benefits was 91.08 million yuan, an increase from 80.23 million yuan[25] - Cash paid for taxes and fees was 19.65 million yuan, up from 11.35 million yuan[25] Expenses and Costs - R&D expenses rose by 30.75% to RMB 48.36 million, primarily due to increased share-based payment expenses[9] - Management expenses increased by 36.28% to RMB 20.20 million, mainly due to higher share-based payment expenses[9] - Research and development expenses for the first quarter of 2024 were 48.36 million yuan, a 30.8% increase compared to 36.99 million yuan in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 1.97 billion, a 2.04% increase from the end of the previous year[5] - The company's equity attributable to shareholders of the listed company increased by 4.01% to RMB 1.77 billion[5] - Total assets as of the end of the first quarter of 2024 were 1.97 billion yuan, a slight decrease from 1.93 billion yuan at the end of the previous quarter[17][18] - Total liabilities for the first quarter of 2024 were 202.78 million yuan, a decrease from 231.56 million yuan at the end of the previous quarter[18] - The company's monetary funds at the end of the period amounted to 706,466,702.80 yuan, an increase from 552,789,166.67 yuan at the beginning of the period[16] - The company's trading financial assets at the end of the period amounted to 382,407,725.81 yuan, a decrease from 469,121,238.93 yuan at the beginning of the period[16] - The company's accounts receivable at the end of the period amounted to 504,358,880.07 yuan, a decrease from 522,446,717.63 yuan at the beginning of the period[16] - The company's inventory at the end of the period amounted to 31,527,239.07 yuan, an increase from 28,782,648.84 yuan at the beginning of the period[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 18,425[11] - Forward Investment (Hong Kong) Limited holds 22.00% of the shares, totaling 87,701,616 shares[11] - Hong Kong Securities Clearing Company Limited holds 14.08% of the shares, totaling 56,135,019 shares[11] - Xiamen Yixiang Investment Partnership holds 5.02% of the shares, totaling 20,026,900 shares[11] - Xiamen Keying Investment Partnership holds 4.98% of the shares, totaling 19,866,146 shares[11] - The National Social Security Fund 406 Portfolio holds 4.48% of the shares, totaling 17,866,370 shares[11] Government Subsidies - Government subsidies received during the period decreased by 47.71% to RMB 6.22 million[9]